down arrow

TFF Pharmaceuticals, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals: Major
  • ISIN: US87241J2033
USD
0.07
-0.1 (-60.05%)

Dec 13

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

0.063.23
Valuation
Technical
Day's Volume

CASH

0

Shareholding (Sep 2024)

FII

0.06%

Held by 4 FIIs

DII

97.76%

Held by 2 DIIs

Promoter

0.00%

How big is TFF Pharmaceuticals, Inc.?

22-Jun-2025

As of Dec 13, TFF Pharmaceuticals, Inc. has a market capitalization of 0.29 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a consolidated net profit of -18.52 million over the latest four quarters. As of Dec 23, the company's shareholder's funds are 9.57 million, and total assets amount to 12.03 million.

Market Cap: As of Dec 13, TFF Pharmaceuticals, Inc. has a market capitalization of 0.29 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, TFF Pharmaceuticals reported net sales of 0.00 million and a consolidated net profit of -18.52 million.<BR><BR>Balance Sheet Snapshot: As of Dec 23, the company's shareholder's funds stand at 9.57 million, while total assets amount to 12.03 million.

Read More

What does TFF Pharmaceuticals, Inc. do?

22-Jun-2025

TFF Pharmaceuticals, Inc. is an early-stage biopharmaceutical company specializing in drug products developed through its Thin Film Freezing technology. It operates in the micro-cap market with a recent net profit of -$4 million and a market cap of $0.29 million.

Overview: <BR>TFF Pharmaceuticals, Inc. is an early-stage biopharmaceutical company focused on developing and commercializing drug products based on its Thin Film Freezing (TFF) technology platform within the Pharmaceuticals: Major industry and operates in the micro-cap market.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -4 Million (Quarterly Results - Sep 2024) <BR>Market cap: USD 0.29 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.81 <BR>Return on Equity: -588.46% <BR>Price to Book: 0.09<BR><BR>Contact Details: <BR>Address: 2600 Via Fortuna Ste 360, AUSTIN TX: 78746-7983 <BR>Website: https://tffpharma.com/

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals: Major

stock-summary
Market cap

USD 0 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.81

stock-summary
Return on Equity

-588.46%

stock-summary
Price to Book

0.09

Revenue and Profits:
Net Sales:
(Quarterly Results - Sep 2024)
Net Profit:
-4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-97.06%
0%
-97.06%
6 Months
-96.43%
0%
-96.43%
1 Year
-99.21%
0%
-99.21%
2 Years
-93.23%
0%
-93.23%
3 Years
-99.17%
0%
-99.17%
4 Years
-99.98%
0%
-99.98%
5 Years
-98.72%
0%
-98.72%

TFF Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-184.55%
EBIT to Interest (avg)
-24.83
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.81
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
24.13%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.09
EV to EBIT
0.11
EV to EBITDA
0.12
EV to Capital Employed
-2.27
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-588.46%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Bearish
Bearish
OBV
Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (2.18%)

Foreign Institutions

Held by 4 Foreign Institutions (0.06%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2024 is 0.00% vs 0.00% in Sep 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2024 is 20.45% vs 39.73% in Sep 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.60",
          "val2": "-4.50",
          "chgp": "20.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.50",
          "val2": "-4.40",
          "chgp": "20.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 33.33% vs -2.58% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.10",
          "val2": "-31.90",
          "chgp": "30.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-21.20",
          "val2": "-31.80",
          "chgp": "33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'24 - YoYstock-summary
Sep'24
Sep'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-3.60
-4.50
20.00%
Interest
0.00
0.00
Exceptional Items
0.00
-0.10
100.00%
Consolidate Net Profit
-3.50
-4.40
20.45%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Sep 2024 is 0.00% vs 0.00% in Sep 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2024 is 20.45% vs 39.73% in Sep 2023

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-22.10
-31.90
30.72%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-21.20
-31.80
33.33%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 33.33% vs -2.58% in Dec 2022

All Annual Resultsstock-summary
stock-summaryCompany CV
About TFF Pharmaceuticals, Inc. stock-summary
stock-summary
TFF Pharmaceuticals, Inc.
Pharmaceuticals: Major
TFF Pharmaceuticals, Inc. is an early-stage biopharmaceutical company. The Company is focused on developing and commercializing drug products based on its Thin Film Freezing (TFF) technology platform. Its TFF platform is designed to enable solubility of poorly water-soluble drugs. Its drug candidates include TFF Vori, TFF Tac-Lac and Triple Combination For chronic obstructive pulmonary disease (COPD)/Asthma. It is developing TFF Vori for the treatment of invasive pulmonary aspergillosis (IPA). TFF Vori is being developed as an inhaled dry powder drug. It is developing TFF Tac-Lac for Immunosuppression to prevent organ transplant rejection. TFF Tac-Lac is being developed as a dry powder version of Tacrolimus, an immunosuppressive drug used in transplant medicine. It is also developing a combination dry powder drug intended for use with a dry powder inhaler for the maintenance treatment of bronchospasm associated with moderate to severe COPD.
Company Coordinates stock-summary
Company Details
2600 Via Fortuna Ste 360 , AUSTIN TX : 78746-7983
stock-summary
Tel:
stock-summary
https://tffpharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."